Lortab 10

Quick links to important sections

Lortab 10

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lortab 10

Quick Facts about Lortab 10

Property Description
Active Ingredients Hydrocodone Bitartrate & Acetaminophen
Form Oral Tablet
Pharmacological Class Opioid Analgesic Combination
General Therapeutic Use Management of moderate to moderately severe pain
Origin Synthetic (Semi-synthetic opioid component)

Lortab 10: Understanding the Medication's Core Identity

Lortab 10 is a synthetic, prescription-only medication classified as an opioid analgesic combination, formulated as an oral tablet. This combination drug is clinically recognized for its effectiveness in managing pain that is severe enough to require an opioid treatment, where alternative options have been inadequate or poorly tolerated. As a result of the hydrocodone component, the medication is subject to strict governmental controls, reflecting its potential for misuse and the need for careful medical oversight.


What is the Composition of Lortab 10? (Hydrocodone and Acetaminophen)

Lortab 10 consists of two active ingredients: Hydrocodone Bitartrate and Acetaminophen (APAP). Hydrocodone is the semi-synthetic opioid agent, which works centrally. Acetaminophen is a non-opioid analgesic that enhances the pain-relieving effects of the combination. The synergistic action of these two components is a key feature of the drug's formulation, a design strategy shared by other commonly prescribed combination products. The number "10" in the Lortab 10 brand name specifically refers to the 10 mg strength of the Hydrocodone component in the tablet.


What is Lortab 10 Prescribed For?

The primary therapeutic purpose of Lortab 10 is the management of moderate to moderately severe pain, such as that experienced following injury or dental surgery. The medicine is intended to be used only when the patient's level of discomfort dictates the necessity of an opioid analgesic, helping to provide substantial relief during periods of acute pain.

Regulatory References

  1. NIH StatPearls
  2. NCI Drug Dictionary

What side effects are possible with Lortab 10?

Possible Side Effects and Safety Information

The official safety information for Lortab 10 (hydrocodone bitartrate and acetaminophen) highlights specific adverse reactions and significant safety risks associated with its two components.

Most Frequently Reported Adverse Reactions

The most frequently reported adverse reactions include lightheadedness, dizziness, sedation, nausea, and vomiting. These effects are often noted as being more prominent in ambulatory (non-bedridden) patients and may be lessened if the patient is lying down.

Serious and Clinically Significant Risks

Hydrocodone is associated with the risk of dose-related respiratory depression (slowed or shallow breathing), which can be life-threatening. The acetaminophen component has been linked to acute liver failure (hepatotoxicity), at times resulting in liver transplant and death, most often when the maximum daily dosage is exceeded. Rare but serious skin reactions, such as Stevens-Johnson Syndrome (SJS), have also been reported with acetaminophen.

Due to its opioid nature, the medicine has a serious regulatory warning for its potential for addiction, abuse, and misuse that can lead to overdose and death. Chronic use can lead to physical dependence and tolerance.

Other System-Organ Adverse Reactions

Adverse reactions documented across various body systems include:

  • Central Nervous System: Drowsiness, mental clouding, lethargy, anxiety, fear, and mood changes.
  • Gastrointestinal System: Constipation may occur with prolonged administration. Other effects include spasm of the sphincter of Oddi.
  • Genitourinary System: Ureteral spasm and urinary retention have been reported with opiates.
  • Special Senses: Cases of hearing impairment or permanent loss have been reported predominantly in patients with chronic overdose.

Population-Specific Considerations

This medication must be used with caution in certain patients, including the elderly and those with severe hepatic or renal impairment, as these groups may be at a greater risk for toxic reactions. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome in the newborn. The drug is generally contraindicated in patients with significant respiratory depression or known/suspected gastrointestinal obstruction.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Lortab 10 (hydrocodone and acetaminophen) is a potentially life-threatening medical emergency defined by dual toxicity. Immediate medical attention is required for any suspected overexposure, as mandated by regulatory documents.

Component Documented Overdose Manifestations
Hydrocodone (Opioid) Profound sedation, miosis (pinpoint pupils), confusion, decreased level of consciousness, and life-threatening respiratory depression.
Acetaminophen (APAP) Initial symptoms include nausea, vomiting, diaphoresis, and general malaise, which can progress to acute liver failure (hepatotoxicity), sometimes requiring a liver transplant.

Severe Outcomes and Required Actions

Regulatory documents classify the most serious risks as fatal respiratory depression and severe acute liver failure. Call emergency services right away if signs of overdose are present, particularly slow or shallow breathing. Specific antidotes are designated for management: Naloxone is indicated to reverse opioid-induced respiratory depression, and N-acetylcysteine (NAC) is the specific antidotal therapy required to mitigate acetaminophen-induced liver damage. Treatment procedures include establishing a patent airway, providing assisted ventilation, and initiating supportive care. Accidental ingestion of even one dose by a child is considered a critical risk and mandates urgent medical evaluation.

Therapeutic Uses of Lortab 10

The combination analgesic Lortab 10 (hydrocodone/acetaminophen) is commonly used for the management of pain classified as moderate to moderately severe. Its application is generally indicated when the patient's symptoms related to physical discomfort are significant enough to require an opioid treatment, and when alternative non-opioid pain options have been insufficient or are not appropriate.

Targeting Pain Classified as Moderate to Moderately Severe

Lortab 10 is generally used to help address symptom clusters that may become intense or disruptive, specifically focusing on heightened physiological activity related to pain. It supports the easing of the overall symptom load in conditions presenting with systemic or localized discomfort. The combination analgesic is considered relevant for easing symptoms that create noticeable physiological strain, which supports general well-being during symptomatic phases.

Symptomatic Relief in Acute Clinical Contexts

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as the acute pain experienced following surgical procedures, severe dental extractions, or certain traumas. Applied in clinical settings that involve acute or unstable symptom patterns, it contributes to symptomatic relief, which may help patients cope more steadily with symptom fluctuations. This assistance with managing discomfort, commonly used when short-term symptomatic assistance is needed, may assist with supporting day-to-day comfort and movement during recovery phases.

Quick Fact: Symptomatic Relief Domains
Applied in clinical settings that involve acute or unstable symptom patterns, relevant for easing symptoms that create noticeable physiological strain, and supports the easing of the overall symptom load during difficult episodes.

Regulatory References

  1. National Library of Medicine MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lortab 10 — Official Regulatory Information

Eligibility Scope

Classification Population/Condition Regulatory Status
Allowed Use Adults Indicated for use in the adult population for moderate to moderately severe pain.
Contraindicated Hypersensitivity to Hydrocodone or Acetaminophen Absolute prohibition against use.
Contraindicated Acute/Severe Asthma, GI Obstruction Absolute prohibition in the absence of resuscitative equipment or due to risk of paralytic ileus.

Age- and Condition-Related Rules

Restriction Type Population/Condition Regulatory Status
Age Limitation Pediatric Patients Safety and effectiveness have not been established for the tablet formulation in children.
Caution Required Geriatric Patients (65+) Use requires caution due to increased sensitivity and potential for confusion or over-sedation.
Organ Function Hepatic or Renal Impairment Use requires caution due to the risk of drug accumulation and potential acetaminophen-related hepatotoxicity.
Life Stage Pregnancy (Prolonged Use) Restricted use; prolonged use can result in Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.
Life Stage Lactation/Breastfeeding Restricted use; components are excreted into human milk, necessitating monitoring or drug discontinuation.

Eligibility Classifications (High-Level)

The official regulatory profile for Lortab 10 is defined by two primary severity levels: Contraindicated (absolute prohibition) and Conditional Use / Caution Required (mandatory risk assessment). These constraints are established in FDA and NIH labeling, outlining eligibility based on pre-existing conditions, age, and physiological states. Use is strictly limited to the adult population for whom efficacy is established.

What should I know about interactions with other medicines?

Lortab 10, a combination of hydrocodone and acetaminophen, can interact with various medications and substances, potentially leading to serious adverse effects.

High-Risk and Contraindicated Combinations

Interacting Product Category Potential Effect Interaction Type
CNS Depressants (including alcohol, other opioids, benzodiazepines, sedatives, tranquilizers, general anesthetics) Profound sedation, respiratory depression, coma, and death due to additive CNS depressant effects. Serious Risk; Limit Use
MAO Inhibitors (e.g., Isocarboxazid, Phenelzine, Safinamide) Dangerous drug interaction; must not be used within 14 days. Contraindicated
Other Acetaminophen Products Exceeding 4,000 mg of acetaminophen daily increases the risk of acute liver failure. Serious Risk; Avoid

Other Clinically Significant Interactions

  • Serotonergic Drugs (including SSRIs, SNRIs, TCAs, Triptans): Concomitant use may result in the development of serotonin syndrome, a potentially life-threatening reaction.
  • CYP3A4 Inhibitors (e.g., certain antibiotics, antifungals): May increase hydrocodone plasma concentration, leading to increased or prolonged opioid effects and risk of respiratory depression.
  • CYP3A4 Inducers (e.g., Rifampin, Phenytoin): May decrease hydrocodone plasma concentration, reducing efficacy or causing opioid withdrawal symptoms.
  • Coumarin Anticoagulants (e.g., Warfarin): The acetaminophen component may affect the anticoagulant effect, requiring close monitoring.
  • Opioid Antagonists (e.g., Naltrexone, Samidorphan): May precipitate acute opioid withdrawal symptoms.

Mechanism of Action

How Lortab 10 Works

Lortab 10 exerts its action through two distinct pharmacodynamic mechanisms in the central nervous system (CNS). The hydrocodone component functions as a mu-opioid receptor (MOR) agonist . Its binding to MORs initiates an inhibitory G-protein coupled cascade, which subsequently modulates the release of key neurotransmitters, resulting in decreased neuronal excitability in primary afferent and dorsal horn pathways.

Simultaneously, the acetaminophen component involves the inhibition of cyclooxygenase (COX) enzymes, predominantly within the CNS. This enzymatic suppression restricts the biosynthesis of prostaglandins within the brain and spinal cord, which in turn modulates the activity within central nociceptive processing systems .

The combined actions of MOR agonism and central COX inhibition modify key ascending and descending neural pathways. This dual-pathway effect ultimately influences signal transmission and processing within the spinal cord and supraspinal centers, altering the physiological communication of nociceptive information.

Dosage and Administration Information

How to Use Lortab 10: Official Administration Guidelines

The usage protocol for Lortab 10 (hydrocodone bitartrate and acetaminophen) is strictly defined and focuses on the high-level, procedural aspects of administration, not on clinical judgment or therapeutic outcomes. The medicine is intended for short-term, intermittent use for acute pain management.


Administration Scope

Category Official Instruction
Route of Administration Exclusively Oral (by mouth). The oral solution/elixir is also an approved liquid form.
Dosing Schedule The standard adult dose is one tablet (10 mg hydrocodone / 325 mg acetaminophen) to be taken every 4 to 6 hours as needed for discomfort. The total dose of the acetaminophen component from all sources must not exceed 4 grams in a 24 hour period.
Administration Conditions The tablet may be taken with or without food.

Procedural Constraints and Special Populations

Category Procedural Rule/Adjustment
Tablet Handling The tablet form is not designed to be crushed or split and must be swallowed whole.
Discontinuation Following prolonged administration, the medicine should be discontinued by gradually tapering the dose to help prevent opioid withdrawal symptoms.
Population Adjustments Older adults and patients with hepatic impairment (liver issues) may require a lower starting dose or careful adjustment due to increased sensitivity and reduced metabolic capacity.
Missed Dose Rule A missed dose should be taken when pain recurs, provided the recommended 4- to 6-hour interval has passed since the previous dose.

These instructions establish the standardized approach to usage, defining the fixed oral route, the required dosing interval, and the absolute maximum daily limits, which are procedural constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lortab 10

Evidence for Use in Acute Moderate to Moderately Severe Pain

The core evidence available for hydrocodone/acetaminophen was derived from short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and were designed to evaluate how the combination drug compared against an inactive substance (placebo). The study populations primarily involved adult subjects in controlled settings, such as those experiencing acute discomfort following a surgical or severe dental procedure.

Findings describe patterns observed in the studies that showed different measurements compared to placebo, concentrating on measured changes in the immediate hours following a dose. The research primarily provides insight into short-term changes during episodes where symptoms become more noticeable, where researchers measured patient-reported outcomes describing perceived discomfort.

Comparative Studies with Other Analgesics

Research has explored the design of clinical studies comparing the hydrocodone/acetaminophen combination against other pain relief options, including certain non-opioid medications and other opioid combinations. Findings indicate that, in some acute pain models, the patterns of measured change observed were similar to those recorded with certain non-opioid analgesic combinations. This research provides context regarding the measurements observed for short-term changes when compared against a variety of other treatments within the study context.

Long-Term Outcomes and Follow-up Duration

The primary studies supporting the clinical evaluation of this medication were based on research exploring short-term symptom changes, often involving follow-up durations that were limited to a matter of hours or days. The existing evidence base is heavily weighted toward these acute, immediate-relief research scenarios.

Long-term effects related to managing pain that persists over months are not fully established in the existing body of randomized controlled trials. Studies focusing on outcomes related to systemic or functional imbalance over a prolonged period are limited, and research describing continuous use over many weeks or months provides a less certain context compared to the short-term trials.

Overview of Evidence Gaps and Research Uncertainties

One key research limitation is that the primary findings describe group patterns observed in controlled studies; research does not provide context for individual predictions, as results apply only to the populations studied. Therefore, the research provides limited context regarding its potential use in chronic pain management. Comparative evidence is also lacking in some research scenarios, and there is limited information derived from observational settings evaluating daily-life functioning over extended periods for this combination drug.

Key Studies & References

  1. Systematic Review on Treatments for Acute Pain: Surveillance Report 1 (Covers evidence on opioid vs. non-opioid combinations)
  2. Hydrocodone and Acetaminophen - StatPearls (General evidence summary and regulatory context)

Frequently Asked Questions (FAQ)

Common questions about Lortab 10 (FAQ)


Q: How long does the pain relief from Lortab 10 typically last?

A: Official product information on the hydrocodone component indicates a typical elimination half-life of 3.8 to 6 hours. This timeframe generally correlates with the drug's effect. The typical dosing schedule provided is every four to six hours as needed for pain, which aligns with the drug's established duration of action.


Q: Is it safe to drive or operate machinery after taking Lortab 10?

A: Regulatory warnings state that Lortab 10 may cause side effects such as dizziness, drowsiness, and mental clouding. Individuals should avoid operating machinery or driving until they understand the full impact of the medication on their alertness and coordination.


Q: Does Lortab 10 cause constipation, and if so, how do you manage it?

A: The use of Lortab 10 may cause constipation, particularly with ongoing administration. Official patient information notes that strategies for managing constipation, such as dietary adjustments or over-the-counter treatments, may be reviewed with a healthcare provider.


Q: Can Lortab 10 affect your mood or cause depression?

A: Adverse reactions reported in safety data include mood changes and mental depression related to the central nervous system. If noticeable changes in emotional state occur while using this medication, it is important to bring these concerns to the attention of a healthcare professional.


Q: Are there any foods or drinks to avoid while taking Lortab 10?

A: Alcoholic beverages should not be consumed, as combining them with Lortab 10 can significantly increase the risk of serious side effects, including extreme drowsiness and slowed breathing. Patients are generally advised to maintain a normal diet otherwise.


Q: Are there any known interactions between Lortab 10 and muscle relaxers?

A: Lortab 10 should be used with caution if taken alongside other central nervous system (CNS) depressants, such as muscle relaxers, sedatives, or tranquilizers. Combining these medications is associated with a serious regulatory precaution due to the potential for profound sedation and slowed breathing.


Q: What are the signs of a possible allergic reaction to Lortab 10?

A: Signs of a serious allergic reaction (hypersensitivity) may include rash, hives, difficulty breathing, hoarseness, or swelling of the face, mouth, or throat. These signs indicate a need for immediate emergency medical evaluation.


Q: Can Lortab 10 cause confusion in some patients?

A: Confusion and mental clouding have been reported as side effects of this medication. Official precautions specifically note that elderly patients may be at an increased risk for experiencing confusion and over-sedation.


Q: Does Lortab 10 interact with common supplements like St. John's Wort?

A: Yes, St. John’s wort and certain other nonprescription products are listed as having potential interactions with hydrocodone combination products. Regulatory guidance highlights the importance of discussing all medications and supplements with a healthcare professional.


Q: What are the signs that Lortab 10 might be interacting badly with another medicine?

A: Signs of a severe drug interaction can include increased confusion, profound drowsiness, difficulty breathing, agitation, fever, or a fast heartbeat. If symptoms such as these occur, immediate medical evaluation is recommended.


Q: Is it possible for Lortab 10 to cause a rapid heartbeat?

A: A rapid heartbeat (tachycardia) has been reported in patient safety data following the use of this medication. However, it is not listed among the most common adverse reactions.


Q: What information should I tell my doctor before starting Lortab 10?

A: Official patient information recommends disclosing all existing health conditions, especially any history of breathing issues, liver or kidney disease, or thyroid problems. Disclosing all other medications, supplements, or nonprescription drugs currently being taken is also recommended as part of the safety profile review.


Q: Can Lortab 10 cause dry mouth?

A: Yes, dry mouth has been reported as an adverse reaction associated with the use of Lortab 10, according to patient safety data.


Q: Does Lortab 10 affect blood pressure?

A: Patient safety data indicates that the drug may cause low blood pressure (hypotension). This effect can sometimes lead to dizziness or lightheadedness, particularly when an individual stands up quickly.


Q: Is it normal for Lortab 10 to cause sweating?

A: Yes, an increase in sweating has been reported as an adverse reaction to Lortab 10 in official patient safety information.


Q: Can Lortab 10 affect my ability to fall asleep or stay asleep?

A: The drug commonly causes sedation and drowsiness, which can alter sleep patterns. In contrast, patient safety data also indicate that some individuals may less frequently experience difficulty falling or staying asleep (insomnia).

How should Lortab 10 be stored and disposed of?

Official Storage and Security Requirements

Lortab 10 tablets must be stored at Controlled Room Temperature, which is officially defined as 15 to 30 C (59 to 86 F). The medication should be dispensed and kept in a tight, light-resistant container with a child-resistant closure to maintain its stability and integrity.

Secure storage is mandatory. The product must be stored securely, out of the sight and reach of children, and in a location that is not accessible to others, including visitors to the home, due to the high risk of fatal accidental ingestion.

Official Disposal Instructions

Expired, unwanted, or unused tablets must be disposed of promptly. If a drug take-back program or mail-back option is not immediately available, the FDA's labeling instructs that the unused medication be disposed of by flushing it down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lortab 10 found in:

A-Z Index: